Novo, Pfizer and Nan Fung helped provide $93.5m for the cancer treatment developer as it advances its lead product candidate towards the clinic.

US-based cancer therapy developer Bolt Biotherapeutics closed a $93.5m series C round yesterday backed property development group Nan Fung and pharmaceutical firms Pfizer and Novo. Venture capital firm Sofinnova Investments led the round, which also featured RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital, Vivo Capital and undisclosed additional investors. Pfizer invested in…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.